XCancer
Clarity Pharmaceuticals

A Phase I/II Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617.

Description:

The aim for this study is to determine the safety and efficacy of 67Cu-SAR-BBN in participants with Gastrin Releasing Peptide Receptor (GRPR)-expressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA-617.

Sponsor:

Clarity Pharmaceuticals

Phase:

Phase 1/2

Contacts:

Clarity Pharmaceuticals (Clarity Clinical)

clinicaltrials@claritypharmaceuticals.com

+61 0 2 9209 4037

Government Study Link:

NCT05633160 - Click here to see study on

ClinicalTrials.gov

Inclusion
  • • Eastern Cooperative Oncology Group performance status of 0 to 2
  • •≥1 Metastatic lesion that is present at screening
  • • Castrate level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L)
  • • Have progressive metastatic castration-resistant prostate cancer (mCRPC)
  • • Histological, pathological, and/or cytological confirmation of Prostate cancer (PCa)
Exclusion
  • • Spinal metastasis with symptomatic cord compression, or clinical or radiologic findings
  • • Prior history of leukemia or Myelodysplastic Syndrome
  • • Histologic diagnosis of small cell prostate cancer
  • • Symptomatic Brain metastasis

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Loading...